

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia ID1647

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis (inclisiran) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • BEMDA: Black and Ethnic Minority Diabetes Association • Black Health Agency • Blood Pressure UK • British Cardiac Patients Association • Cardiovascular Care Partnership • Circulation Foundation • Diabetes Research and Wellness Foundation • Diabetes UK • Genetic Alliance UK • HEART UK • InDependent Diabetes Trust • JDRF • Muslim Council of Britain • Network of Sikh Organisations • Pulmonary Hypertension Association UK • Pumping Marvellous Foundation • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses & Counsellors • British and Irish Hypertension Society • British Association for Nursing in Cardiovascular Care • British Atherosclerosis Society • British Cardiovascular Intervention Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare UK (atorvastatin, ezetimibe, fluvastatin, pravastatin, rosuvastatin, simvastatin) • Advanz Pharma (ezetimibe) • Amgen UK (evolocumab) • Aspire Pharma (fluvastatin) • AstraZeneca UK (rosuvastatin) • Aurobindo Pharma (atorvastatin, ezetimibe, pravastatin, rosuvastatin, simvastatin) • Brown and Burk UK (simvastatin)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Heart Rhythm Society • British Inherited Metabolic Disease Group • British Nuclear Cardiology Society • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Society for Heart Failure • British Society for Human Genetics • British Society of Cardiovascular Imaging • Clinical Leaders of Thrombosis • National Heart and Lung Institute • Primary Care Cardiovascular Society • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Endocrinology • Society for Vascular Nurses • Society for Vascular Technology • TREND UK • UK Clinical Pharmacy Association • UK Genetic Testing Network • Vascular Society of Great Britain & Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bradford City CCG • NHS Eastern Cheshire CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Consilient Health (atorvastatin, rosuvastatin) • Dexcel Pharma (atorvastatin) • Flamingo Pharma UK (atorvastatin) • Glenmark Pharmaceuticals (ezetimibe, rosuvastatin) • Lupin Pharmaceuticals (simvastatin) • Merck Sharp & Dohme (ezetimibe, simvastatin) • Mylan UK (atorvastatin, ezetimibe, fluvastatin, pravastatin, rosuvastatin) • Novartis Pharmaceuticals UK (fluvastatin) • Pfizer (atorvastatin) • Rosemont Pharmaceuticals (simvastatin) • Sandoz (ezetimibe, fluvastatin, rosuvastatin, simvastatin) • Sanofi (alirocumab) • Sun Pharmaceuticals (atorvastatin, rosuvastatin) • Wockhardt UK (atorvastatin) • Zentiva UK (atorvastatin, ezetimibe, rosuvastatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiac and Cardiology Research Department, Barts • Central Cardiac Audit Database • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Stroke Group • European Council for Cardiovascular Research • Genomics England • Heart Research UK • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • National Institute for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.